Initial report on the month 12 results from the Psoriasis Study of Health Outcomes (PSoHO) for patients with moderate-to-severe psoriasis treated with biologics in the real-world setting

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• PSoHO is a 3-year prospective, no-interventional study comparing anti-IL-17A agents with other approved biologics in psoriasis.
• In this analysis, response rates were higher for patients receiving anti-IL-17A therapies compared to other biologics.
• 61.5% of anti-IL-17A patients maintained at least PAI90 and sPGA 0/1 at Months 6 and 12, compared to 46.3% on other biologics.
• 25.3% of those who achieved PASI100 at Week 12 maintained it to Month 12 with anti-IL-17A, compared to 13.7% with other biologics.
• Durability of effectiveness at Month 12 was highest for patients treated with anti-IL-17A: 64% compared to 49% for other biologics